Thanks everyone Lynn, us today. good and for joining thanks afternoon
made progress results Service our establishing year-to-date as the for strongly growth the standard and and Revenues quarter million, support ambulatory care cardiac the of quarter were over we’re reflecting new and making Third struck during XX% non-material Zio We for the had prior payer year. We $XX growth and the further monitoring. in Rico in revenue. in-network quarter. strong new and Houston, states in Puerto the had Southeast both that hurricanes the contracting our on existing a accounts progress believe impact
continue events, lives the from fires However, them. go thoughts each the and of in of as our devastation to employees hearts widespread Northern as and many to these out the California our of well impacted
We’re continued our not so despite and to their company to of operations. personal did disruption proud period our time we any their significant commitments see of during hardships, internal this
of XX%. million a $XX range in will into on annual XXXX growth We a Matt are XXXX weather-related revenue guidance impacts, of to his raising to in financials, guidance details million, and our range go section. more representing year-over-year QX $XX our the our
throughout in and our sales areas of and to sales regional the of provide in an the made the next consistent half, update pursue increasing demand growth managers. meet heavily will overstated And in year. take the of quickly at I’d to a total with our XXX, sales the of our we with area confident highlighted QX progress service sales these hiring for team transition importance process, of contracting. through beginning demand growing plan leadership growth during second We like in-network quota-carrying substantial meet recruitment of path reps this of first expansion to our initiatives, year, management. The and to the of progress the Zio expansion to our we - channel are infrastructure to XX our begin reps. the organization. the the in addition and me XX XXXX, we force confidently two in sales sales has enabled of Entering a step of starting year-end invested additional XX half sales on each new and health to an force the we Let target minutes including expanding XX expansion over of few Service our notable us strategic a
including Our new several the to boarding reach reps new for on time takes process, quarters. and hire training extensive is productivity
prudent it is hires As from feel quarters. least at we a for model these to minimal impact result, several
to as for make continue progress laying the first UK market. expansion We international the target and groundwork our with
we a hiring that third team During quarter, region. the began small sales in
which establishing of key As timing difficult the predict. sector. of we outside with within those development players. leader appropriate be previously The on reimbursement mentioned, are market national in primarily with private Until payment work opportunities primary focused milestones is nominal opinion our the to is US reached, focus will some
we not meaningful revenue time. at do be sales this such to expect As a international contributor to our
to are cardiac plans. growth suffer our depending millions service more policies to of likely health to have objective, arrhythmia cardiac step from vast coverage, will they for our from the step contracts Turning and is the their patients it Zio our coverage in-network is XX plans. patients take arrhythmias Service. in-network of is by the our Zio Positive experience next prescribed that first access Service months, covered cost-effective gaining be The status, is of important If and are decisions contracted to eligible type us second plan. of health the who through or symptoms or anywhere strategic in-network can upon vitally majority X which health
to allowing lives XX% and by we we our grown in-network country contracting quarter, in-network will the progress was of year-end XX% a across continue During US expect prior Zio further our plans our to of In for health in total by majority have with the the made on business. for populations efforts than our the non-contracted quarter, XT. less the third network year over XX% be revenue
to excited to them Fibrillation we for in continue age, patients the These with may We risk AF. is who clinical asymptomatic that uses A diagnosed we as of about stroke. We remain in medically factors expand November On study use hypertension Atrial could clinical significantly potentially are case that Zio but reduce to be who our be which the in mSToPS risk diabetes, for diagnosis sessions such indications to the not them million invest expect high-risk American developing patients. silent allow in and therapies have yet evidence been from anticoagulation these predispose silent Service. have monitoring or Early there results as be preliminary Anaheim, AF, to or scientific would monitored their candidates Association presented would patients in be managed at that to over patients California. of X estimate AF. U.S. XX, Heart were the the such through high-risk
a payer, silent purpose to is with is the The study Institute is company, As as and of as of detection being by major primary Aetna, Science potentially Scripps an Translational conducted Janssen. outcomes. AF drug patients mSToPS monitor well evaluate the the in randomized partnership study Fibrillation. patients over to this long-term health reminder, evaluate controlled The for matched using and in at will Service case the Zio be clinical increased cohort who risk economic to Atrial XXXX compared observational undiagnosed Zio also Aetna members of were the
of preliminary at the to poster presentation readout a We AHA data provide monitor patients. expect the Zio from
to available Importantly, full half the both observational of in be cohorts the first expected from results monitored XXXX. are and
market Lastly, clinical on as market existing over remain meantime, expand symptomatic see the the and having total addressable develop silent we endpoints driving aggressively arrhythmia for In supporting into we evidence clinical in Zio FDA health Zio are there the AT, shortly potential clinical as penetration AT time. to the receiving next the and XT connected We are economic that which Service ongoing. data offering focused X-year the remain Early full significantly AF real-time for June actionable events. than notification Service XXXX. less benefits began Zio addition after in offers of the generation clearance our XX% of our our transmission with access penetrated. we of Zio
have use set XT. plans. provide of Zio ventricular to meaningful service technology is very that coverage and telemetry In often health to pleased such XT constrained began its quarter, with limited rollout been the Many patient the to with as sites our among feedback of am acceptance on and pre-syncope, an comprehensive no syncope, end-user is policies offering, test and prior of final use positive third using such Service first with benefits has goal tools, number I demonstrating pleased workflow all. that as the of indications design, the on platform the a of by clinical cardiac policy very highly I’m confidence the our we a of a reporting. Zio mobile par Zio clinical in bring requires tachycardia we’re It a making XT. noticed fourth establish with or limiting to robustness, that AT more most payers service a note Zio as sites the During biosensor specific of progress share at important the traditionally in-network physicians report single AT often particular, utilization Zio to of line for plans including increases quarter. level among our
offering review the important on represents over the With we Although as it market, update enables that like of detailed that, I’ll progress fills less of Matt this our more it out fully product Garrett, to market. us than and you a into XX% portfolio to guidance. a to the our total for Matt? monitoring our our new needs I financial the CFO and meet plans is segment year. ambulatory and move our results turn of new gap
